HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Impacto

Downloads

Downloads per month over past year

Bueno Muiño, Coralia and Martín, Miguel and Monte Millán, María del and García Saénz, José Ángel and López Tarruella, Sara (2022) HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. Cancers, 14 (3). p. 512. ISSN 2072-6694

[thumbnail of cancers-14-00512-v2.pdf]
Preview
PDF
Creative Commons Attribution.

323kB

Official URL: https://doi.org/10.3390/cancers14030512




Abstract

Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies.


Item Type:Article
Uncontrolled Keywords:early; HER2+; escalation; de-escalation; intrinsic subtype; HER2-enriched
Subjects:Medical sciences > Medicine > Oncology
ID Code:72849
Deposited On:16 Jun 2022 16:30
Last Modified:17 Jun 2022 07:09

Origin of downloads

Repository Staff Only: item control page